Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2025 16:35 ET | Source: FibroBiologics, Inc.

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the...
June 16, 2025 09:50 ET | Source: FibroBiologics, Inc.

FibroBiologics to Present at the BIO International Convention 2025

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the...
June 09, 2025 08:30 ET | Source: Fibrobiologics, Inc.

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the...
May 16, 2025 08:30 ET | Source: Fibrobiologics, Inc.

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the...
May 14, 2025 16:30 ET | Source: Fibrobiologics, Inc.

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of...
April 29, 2025 09:15 ET | Source: Fibrobiologics, Inc.

FibroBiologics Presents at the ThymUS 2025 Meeting

HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the...
April 11, 2025 08:30 ET | Source: Fibrobiologics, Inc.

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of...
April 08, 2025 08:30 ET | Source: Fibrobiologics, Inc.

FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics

HOUSTON, April 08, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”) , a clinical-stage biotechnology company with 240+ patents issued and pending for the development...
April 02, 2025 22:33 ET | Source: Fibrobiologics, Inc.

FibroBiologics gibt wissenschaftlicher Fortschritte bei der Reparatur von Hirngewebe bekannt

HOUSTON, April 03, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (im Folgenden kurz „FibroBiologics“), ein im klinischen Stadium tätiges Biotechnologieunternehmen mit über 240...
April 02, 2025 22:33 ET | Source: Fibrobiologics, Inc.

FibroBiologics annonce des progrès scientifiques suite à la confirmation des résultats relatifs à la réparation de tissus cérébraux

HOUSTON, 03 avr. 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq : FBLG), ou « FibroBiologics », une société de biotechnologie au stade clinique détenant plus de 240 brevets délivrés et en...